Table 1.
Clinical characteristics of breast cancer patients evaluated at the Cardio-Oncology Unit from 2020 to 2022.
| Breast Cancer Patients (n = 591) | |
|---|---|
| HER2 positive | 36.04% (213) |
| Cancer stage IV | 16.75% (99) |
| Family history of cardiovascular disease | |
| None | 94.25% (557) |
| Sudden death * | 1.52% (9) |
| Cardiomyopathies | 0.68% (4) |
| Premature coronary artery disease | 1.52% (9) |
| Others | 0.17% (1) |
| Second-degree relatives or at an older age | 1.69% (10) |
| Personal history of cardiovascular disease | |
| None | 93.57% (553) |
| Arrythmias | 2.54% (15) |
| Coronary artery disease | 1.86% (11) |
| Valvular heart diseases | 0.68% (4) |
| Prior cardiac dysfunction due to chemotherapy | 1.18% (7) |
| Cardiovascular risk factors | |
| Tabaco consumption | 47.04% (278) |
| Hypertension | 24.03% (142) |
| Diabetes | 7.78% (46) |
| Dyslipidemia | 25.55% (151) |
| Body mass index (kg/m2) | 27.4 (±6.1) |
| Mean of available echocardiogram parameters † |
Basal/Final |
| LVMWT (mm) | 1 ± 0.2/1 ± 0.2 |
| LVTDV (mL) | 46.7 ± 19.4/1 ± 0.2 |
| LVEF | 62 ± 6/61.45 ± 5.8 |
| E/A | 1 ± 0.6/1 ± 0.4 |
| E/e’ | 7.2 ± 2.75/7.2 ± 2.8 |
| GLS † | −20% ± 3.4/−20% ± 0.4 |
| % of patients with significant LVEF reduction in follow-up |
3.7% (22) 7.2% in HER2 positive vs. 1.3% in HER2 negative (p < 0.001) |
| TAPSE | 2.3 ± 0.5/2.23 ± 0.3 |
* Sudden death was considered positive in first-degree relatives and those < 60 years old, to include inherited cardiomyopathies and premature coronary artery disease. LVMWT: left ventricular maximum wall thickness; LVTDV: left ventricular tele-diastolic volume; LVEF: left ventricular ejection fraction (mm); † LVEF evaluation by 3D was unavailable and GLS only in some patients.